Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi : Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021
The safety profiles of the Ad26.COV2.S and AZD1222 COVID-19 vaccines have not been described in the general population in Malawi. We present self-reported adverse events (AE) following the receipt of these vaccines in Malawi as part of a national syndromic surveillance survey. We conducted phone-based syndromic surveillance surveys among adults (≥18 years) with verbal consent. We used secure tablets through random digit dialing to select mobile phone numbers and collected data electronically. Survey questions included whether the respondent had received the COVID-19 vaccines, whether they had experienced any AE following vaccination, and the severity of the AE. We used multivariable analysis to identify factors associated with self-reported AE post-COVID-19 vaccination. A total of 11,924 (36.0%) out of 33,150 respondents reported receiving at least one dose of either Ad26.COV2.S or AZD1222 between July-December 2021; of those, 65.1% were female. About 49.2% of the vaccine recipients reported at least one AE, 90.6% of which were mild, and 2.6% were severe. Higher education level and concern about the safety of COVID-19 vaccines were associated with AE self-report (Adjusted Odds Ratio [AOR] 2.63 [95% CI 1.96-3.53] and 1.44, [95% CI 1.30-1.61], respectively), while male gender and older age were associated with reduced likelihood of AE self-report (AORs 0.81, [95% CI 0.75-0.88], 0.62 [95% CI 0.50-0.77], respectively). Ad26.COV2.S and AZD1222 vaccines are well-tolerated, with primarily mild and few severe AE among adults living in Malawi. Self-reporting of AE following COVID-19 vaccination is associated with gender, age, education, and concern about the safety of the vaccines. Recognizing these associations is key when designing and implementing COVID-19 vaccination communication messages to increase vaccination coverage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
International journal of environmental research and public health - 20(2023), 23 vom: 30. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Makonokaya, Lucky [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AZD1222 |
|---|
| Anmerkungen: |
Date Revised 08.12.2023 published: Electronic Citation Status In-Process |
|---|
| doi: |
10.3390/ijerph20237123 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365544337 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365544337 | ||
| 003 | DE-627 | ||
| 005 | 20231229123019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijerph20237123 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365544337 | ||
| 035 | |a (NLM)38063553 | ||
| 035 | |a (PII)7123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Makonokaya, Lucky |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi |b Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status In-Process | ||
| 520 | |a The safety profiles of the Ad26.COV2.S and AZD1222 COVID-19 vaccines have not been described in the general population in Malawi. We present self-reported adverse events (AE) following the receipt of these vaccines in Malawi as part of a national syndromic surveillance survey. We conducted phone-based syndromic surveillance surveys among adults (≥18 years) with verbal consent. We used secure tablets through random digit dialing to select mobile phone numbers and collected data electronically. Survey questions included whether the respondent had received the COVID-19 vaccines, whether they had experienced any AE following vaccination, and the severity of the AE. We used multivariable analysis to identify factors associated with self-reported AE post-COVID-19 vaccination. A total of 11,924 (36.0%) out of 33,150 respondents reported receiving at least one dose of either Ad26.COV2.S or AZD1222 between July-December 2021; of those, 65.1% were female. About 49.2% of the vaccine recipients reported at least one AE, 90.6% of which were mild, and 2.6% were severe. Higher education level and concern about the safety of COVID-19 vaccines were associated with AE self-report (Adjusted Odds Ratio [AOR] 2.63 [95% CI 1.96-3.53] and 1.44, [95% CI 1.30-1.61], respectively), while male gender and older age were associated with reduced likelihood of AE self-report (AORs 0.81, [95% CI 0.75-0.88], 0.62 [95% CI 0.50-0.77], respectively). Ad26.COV2.S and AZD1222 vaccines are well-tolerated, with primarily mild and few severe AE among adults living in Malawi. Self-reporting of AE following COVID-19 vaccination is associated with gender, age, education, and concern about the safety of the vaccines. Recognizing these associations is key when designing and implementing COVID-19 vaccination communication messages to increase vaccination coverage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AZD1222 | |
| 650 | 4 | |a Ad26.COV2.S | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Malawi | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a mobile phone-based syndromic surveillance survey | |
| 650 | 4 | |a self-report | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Kapanda, Lester |e verfasserin |4 aut | |
| 700 | 1 | |a Woelk, Godfrey B |e verfasserin |4 aut | |
| 700 | 1 | |a Chauma-Mwale, Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Kalitera, Louiser Upile |e verfasserin |4 aut | |
| 700 | 1 | |a Nkhoma, Harrid |e verfasserin |4 aut | |
| 700 | 1 | |a Zimba, Suzgo |e verfasserin |4 aut | |
| 700 | 1 | |a Chamanga, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Golowa, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Machekano, Rhoderick |e verfasserin |4 aut | |
| 700 | 1 | |a Maphosa, Thulani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of environmental research and public health |d 2004 |g 20(2023), 23 vom: 30. Nov. |w (DE-627)NLM162777434 |x 1660-4601 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:23 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijerph20237123 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 23 |b 30 |c 11 | ||